tedizolid; tedizolid phosphate (Sivextro)

^[1]^[2]^[3]

Indications

acute bacterial skin infections & skin-structure infections, including infections with MRSA & Enterococcus faecalis^[1]^[2] (FDA-approved June 2014)
activity against linezolid-resistant S aureus^[3]

a 6 day course of tedizolid phosphate is non inferior to a 10 day course of linezolid^[1]

↑ ^1.0 ^1.1 ^1.2 Prokocimer P et al Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: The ESTABLISH-1 randomized trial. JAMA 2013 Feb 13; 309:559. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23403680
Doron S and Boucher HW. Antibiotics for skin infections: New study design and a step toward shorter course therapy. JAMA 2013 Feb 13; 309:609. PMID: https://www.ncbi.nlm.nih.gov/pubmed/23403687
↑ ^2.0 ^2.1 ^2.2 Young K FDA Advisers Recommend Approval of Two Antibiotics. Physician's First Watch, April 2, 2014 David G. Fairchild, MD, MPH, Editor-in-Chief Massachusetts Medical Society http://www.jwatch.org
FDA News Release. June 20, 2014 FDA approves Sivextro to treat skin infections. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm402174.htm
↑ ^3.0 ^3.1 ^3.2 ^3.3 Medical Knowledge Self Assessment Program (MKSAP) 17, American College of Physicians, Philadelphia 2015